Actuate Therapeutics

16 articles with Actuate Therapeutics

• Actuate Therapeutics Congratulates Dr. Patricia LoRusso on Being Named AACR President-Elect

  3/23/2023

  Actuate Therapeutics, Inc. today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board has been Elected as President-Elect the American Association of Cancer Research for 2023-2024.

• Actuate Therapeutics Congratulates Dr. Patricia LoRusso on Being Named AACR President-Elect

  3/23/2023

  Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib (a novel GSK-3 inhibitor), today announced that Patricia M. LoRusso, DO, PhD (hc), a member of its Scientific Advisory Board, has been elected as President-Elect of the American Association of Cancer Research for 2023-2024.

• Drs. Roger B. Cohen, Lee M. Ellis and John L. Marshall Join Actuate Therapeutics’ Scientific Advisory Board

  10/18/2022

  Actuate Therapeutics, Inc., a Chicago-based clinical-stage biopharmaceutical company advancing lead drug elraglusib, announced the addition of eminent cancer research leaders Roger B. Cohen, MD, Lee M. Ellis, MD, and John L. Marshall, MD to their Scientific Advisory Board.

• Actuate Therapeutics Announces Poster Presentations at the 2022 AACR Annual Meeting

  3/28/2022

  Actuate Therapeutics, Inc. announced today two poster presentations from scientific collaborators at the upcoming American Association for Cancer Research (AACR) Annual Meeting, taking place April 8-13, 2022, in New Orleans, Louisiana.

• 

  Clinical Catch-Up: Covaxin, Celyad Hold, CRISPR's Next Step

  3/7/2022

  The biopharma industry ended February and began March with plenty of clinical trial news. BioSpace shares the highlights.

• Actuate Therapeutics Announces First Patient Enrolled in Phase 2 Clinical Trial of Elraglusib Plus Retifanlimab as Investigational First Line Therapy for Patients With Advanced Pancreatic Cancer

  3/1/2022

  Actuate Therapeutics and The University of Kansas Cancer Center today announced the enrollment of the first patient on a Phase 2 study of elraglusib (9-ING-41) plus retifanlimab combined with gemcitabine/nab-paclitaxel for the treatment of patients with advanced pancreatic cancer in the first-line setting (NCT05239182).

• Actuate Therapeutics Announces Initiation of a Multicenter Randomized Trial of Elraglusib Plus FOLFIRINOX As First Line Therapy for Advanced Pancreatic Cancer

  2/7/2022

  Actuate Therapeutics, Inc. today announced the opening of a randomized study of elraglusib (9-ING-41) plus FOLFIRINOX alone or with Losartan for patients with advanced pancreatic cancer in the first-line setting (NCT05077800).

• Lantern Pharma and Actuate Therapeutics Announce Research & Development Collaboration Leveraging Lantern's Artificial Intelligence Platform

  5/3/2021

  - Collaboration Will Leverage Lantern's RADR® A.I. Platform to Accelerate Development of Actuate's Drug Candidate, 9-ING-41 - Actuate's 9-ING-41 is a Best-In-Class Drug Candidate for Cancer & Fibrotic Diseases - Lantern Will Receive Equity Based on Meeting Development Milestones & May Receive Additional Equity Based on Use of Findings in Future Development

• Actuate Therapeutics Completes $6.5 Million Series B-3 Financing To Expand Clinical Programs

  11/12/2019

  Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, announced it has raised an additional $6.5M in a Series B-3 financing round.

• 

  Actuate Therapeutics Secures $21.7 Million to Support Phase I/II Clinical Trial

  5/17/2019

  The company took its GSK-3B inhibitor into the clinic earlier this year. The drug is being studied in patients with refractory hematologic malignancies or solid tumors.

• ACTUATE THERAPEUTICS COMPLETES $21.7 MILLION SERIES B FINANCING

  5/15/2019

  Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced it has raised $21.7 Million in a Series B financing round.

• ACTUATE THERAPEUTICS OPENS PHASE 1 / 2 CLINICAL STUDY OF 9-ING-41 IN PATIENTS WITH REFRACTORY CANCERS

  12/17/2018

  Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today announced the enrollment of the first patients in its 1801 Phase 1 / 2 study of 9-ING-41, a proprietary glycogen synthase kinase-3 beta (GSK-3β) inhibitor, in patients with refractory hematologic malignancies or solid tumors. 

• Actuate Therapeutics Submits IND Application for Treatment of Refractory Cancers

  1/15/2018

  The clinical trial will be initiated in over 20 world-leading oncology research institutions in the EU and US after successful regulatory reviews of the application. 

• Actuate Therapeutics Receives Rare Pediatric Disease Designation for 9-ING-41 for Treatment of Neuroblastoma

  10/30/2017

  The Rare Pediatric Disease Designation of 9-ING for the treatment of pediatric neuroblastoma comes in addition to Orphan Drug Designations previously granted by the FDA for neuroblastoma, and separately,

• Dr. Daniel Billadeau Joins Actuate Therapeutics’ Scientific Advisory Board

  5/9/2017

• Actuate Therapeutics' Programs Highlighted In Clinical Cancer Research

  4/3/2017